# OnCo record osimertinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/osimertinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "osimertinib" ;
  schema:name "Osimertinib"@en ;
  schema:description "Osimertinib (Tagrisso) is the standard pill for EGFR-mutant lung cancer, now also given after surgery and with chemotherapy or after chemoradiation."@en ;
  schema:url <https://onco.cc/drugs/osimertinib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Osimertinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21506464> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Osimertinib>, <https://www.nice.org.uk/guidance/ta654>, <https://www.nice.org.uk/guidance/ta1043>, <https://www.nice.org.uk/guidance/ta1060>, <https://www.nice.org.uk/guidance/ta1156> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (EGFR)" ;
  schema:alternateName "Tagrisso" ;
  onco:approval "US 2015: EGFR T790M NSCLC", "US 2018: First-line EGFR-mutant NSCLC", "US 2020: Adjuvant EGFR-mutant NSCLC", "England (NICE) 2020: Untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer", "England (NICE) 2020: EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer after a first-line EGFR inhibitor", "England (NICE) 2025: Adjuvant treatment of stage IB to IIIA EGFR exon 19 deletion or L858R non-small-cell lung cancer after complete resection", "England (NICE) 2025: Untreated advanced EGFR mutation-positive non-small-cell lung cancer, with pemetrexed and platinum-based chemotherapy", "England (NICE) 2026: Unresectable stage III EGFR mutation-positive non-small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy" ;
  onco:acceleratedApproval "US 2015-11-13: Metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, that progressed on or after EGFR TKI therapy" ;
  onco:acceleratedApprovalConfirmed "US 2017-03-30: Metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, that progressed on or after EGFR TKI therapy" ;
  onco:related <https://onco.cc/biomarkers/egfr-exon-19-deletion/>, <https://onco.cc/biomarkers/egfr-l858r/>, <https://onco.cc/biomarkers/egfr-t790m/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/resectable-nsclc/>, <https://onco.cc/cancers/stage-iii-unresectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/adaura/>, <https://onco.cc/trials/flaura2/>, <https://onco.cc/trials/nct06350097/>, <https://onco.cc/trials/nct04351555/>, <https://onco.cc/trials/nct06838273/>, <https://onco.cc/trials/nct05120349/>, <https://onco.cc/trials/nct06670196/>, <https://onco.cc/trials/nct02411448/>, <https://onco.cc/trials/nct07640789/>, <https://onco.cc/trials/nct06417814/>, <https://onco.cc/trials/nct07642024/>, <https://onco.cc/trials/nct04765059/>, <https://onco.cc/trials/nct04606771/>, <https://onco.cc/trials/nct06498986/>, <https://onco.cc/trials/nct05801029/>, <https://onco.cc/trials/nct05880706/>, <https://onco.cc/trials/nct07229729/>, <https://onco.cc/trials/nct07622186/>, <https://onco.cc/trials/nct07079475/>, <https://onco.cc/trials/nct04868877/>, <https://onco.cc/trials/nct05816252/>, <https://onco.cc/trials/nct07329322/>, <https://onco.cc/trials/nct05546866/>, <https://onco.cc/trials/nct07206498/>, <https://onco.cc/trials/nct04665206/>, <https://onco.cc/trials/nct07669779/>, <https://onco.cc/trials/nct03944772/>, <https://onco.cc/trials/nct06574347/>, <https://onco.cc/trials/nct04486833/>, <https://onco.cc/trials/nct05785741/>, <https://onco.cc/trials/nct03778229/>, <https://onco.cc/trials/nct06895928/>, <https://onco.cc/trials/nct05261399/>, <https://onco.cc/trials/nct03381274/>, <https://onco.cc/trials/nct06194448/>, <https://onco.cc/trials/nct03040973/>, <https://onco.cc/trials/nct03833154/>, <https://onco.cc/trials/nct07295821/>, <https://onco.cc/trials/nct05948813/>, <https://onco.cc/trials/nct05629234/>, <https://onco.cc/trials/nct06970639/>, <https://onco.cc/trials/nct06618287/>, <https://onco.cc/trials/nct06391944/>, <https://onco.cc/trials/nct05526755/>, <https://onco.cc/trials/nct06868485/>, <https://onco.cc/trials/flaura/>, <https://onco.cc/trials/aura3/>, <https://onco.cc/trials/laura/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-flaura-nejm-2018/>, <https://onco.cc/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/>, <https://onco.cc/key-papers/paper-mariposa-nejm-2024/> .